

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IB05/000752

International filing date: 23 March 2005 (23.03.2005)

Document type: Certified copy of priority document


Document details: Country/Office: US
Number: 60/555,815
Filing date: 24 March 2004 (24.03.2004)

Date of receipt at the International Bureau: 06 July 2005 (06.07.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


June 20, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/555,815

FILING DATE: March 24, 2004

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



M. Tarver

M. TARVER
Certifying Officer

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EL 717 745 489 US**

22151 U.S. PTO
60/555815



INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Marisa E.E.		Jaconi		Geneva, Switzerland	
Additional inventors are being named on the <u>one</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
3D-CARDIAC TISSUE ENGINEERING FOR THE CELL THERAPY OF HEART FAILURE					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number: 23579					
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>22</u>		<input type="checkbox"/> CD(s), Number _____			
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>1</u>		<input checked="" type="checkbox"/> Other (specify) <u>Return Postcard</u>			
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE Amount (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.				\$80.00	
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>50-1868</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

Rivka D. Monheit

TYPED or PRINTED NAME Rivka D. Monheit

TELEPHONE (404) 817-8514

Date March 24, 2004

REGISTRATION NO. 48,731

(if appropriate)

Docket Number: KUROS 110

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

KUROS 110 - 079669/00001

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

KUROS 110

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle (if any))	Family or Surname	Residence (City and either State or Foreign Country)
Prisca	Zammaretti-Schär	Zürich, Switzerland

[Page 2 of 2]

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

KUROS 110 - 079669/00001

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80.00

Complete if Known

Application Number	
Filing Date	March 24, 2004
First Named Inventor	Marisa E.E. Jaconi
Examiner Name	
Art Unit	
Attorney Docket No.	KUROS 110

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:
 Deposit
Account
Number
Deposit
Account
Name

50-1868

Holland & Knight LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80.00
SUBTOTAL (1)					(\$) 80.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		-20* =		X	Fee from below		Fee Paid	
Independent Claims		-3** =		X				
Multiple Dependent								

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

(Complete (if applicable))

Name (Print/Type)	Rivka D. Monheit	Registration No. (Attorney/Agent)	48,731	Telephone	(404) 817-8514
Signature	<i>Rivka D. Monheit</i>	Date	March 24, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

KUROS 110 - 079669/00001

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

We claim:

1. A composition for repair of cardiac tissue comprising a biodegradable matrix, one or more active agents, and stem cells differentiating to form cardiac tissue.
- 5 2. The composition of claim 1 wherein the matrix is formed of a gel.
3. The composition of claim 2, wherein the biodegradable matrix is formed of a material selected from the group consisting of fibrin, collagen, and synthetic polymers mimicking the extra cellular matrix (ECM).
4. The composition of claim 1, wherein the stem cells are embryonic, fetal
10 or adult stem cells.
5. The composition of claim 1, wherein the active agents are selected from the group consisting of growth factors and cytokines.
6. A cardiac patch comprising a fibrin matrix, one or more active agents, and stem cells.
- 15 7. A method for repair of heart tissue comprising implanting into the heart tissue any of the compositions of claims 1-6,.




Figure 1. Technique for the *in vitro* 3D-tissue engineered fibrin gels.

(a) Different multi-well systems are used to produced 3D fibrin gels containing appropriate types of stem cells and growth factors to study their differentiation and tissue formation *in vitro*. (b) Such engineered "cardiac patches" are the implanted onto normal or infarcted rat hearts.

APPLICATION DATA SHEET

Inventor Information

Inventor One Given Name:: Marisa E.E.
Family Name:: Jaconi
Name Suffix::
Postal Address Line One:: Rue Daubin 5
Postal Address Line Two::
City:: Geneva
State or Province::
Country:: Switzerland
Postal or Zip Code:: CH-1203
City of Residence:: Geneva
State or Prov. of Residence::
Country of Residence:: Switzerland
Citizenship Country:: Switzerland

Inventor Two Given Name:: Prisca
Family Name:: Zammaretti-Schär
Name Suffix::
Postal Address Line One:: Frohburgstrasse 324
Postal Address Line Two::
City:: Zurich
State or Province::
Country:: Switzerland
Postal or Zip Code:: CH-8057
City of Residence:: Zurich
State or Prov. of Residence::
Country of Residence:: Switzerland
Citizenship Country:: Switzerland

Correspondence Information:

Correspondence Customer Number:: 23579
Telephone:: 404-817-8473
Fax:: 404-817-8588
Electronic Mail One:: jcstines@hklaw.com
Electronic Mail Two:: ppabst@hklaw.com

U.S.S.N.
Filed: March 24, 2004
Application Data Sheet

Application Information:

Title Line One::	3D-CARDIAC TISSUE ENGINEERING FOR THE
Title Line Two::	CELL THERAPY OF HEART FAILURE
Title Line Three::	
Total Drawing Sheets::	1
Formal Drawings?::	No
Application Type::	Provisional
Docket Number::	KUROS 110
Licensed US Govt. Agency::	
Contract or Grant Numbers One::	
Contract or Grant Numbers Two::	
Secrecy Order in Parent Appl.?::	No

Representative Information

Representative Customer Number:: 23579

1804208_v1

Title: "3D-Cardiac Tissue Engineering For The Cell Therapy Of Heart Failure"
By: Marisa E.E. Jaconi and Prisca Zammaretti-Schär
Filed: March 24, 2004

CERTIFICATE OF MAILING UNDER 37 CFR §1.10

I hereby certify that this **PROVISIONAL APPLICATION**, and any documents referred to as attached therein, are being deposited with the United States Postal Service on this date, March 24, 2004, in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR §1.10, Mailing Label Number EL 717 745 489 US, addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Pam Turnbough

Date: March 24, 2004

1804373_v1

KUROS 110
079669/00001

PROVISIONAL PATENT APPLICATION

BY

MARISA E.E. JACONI

AND

PRISCA ZAMMARETTI-SCHÄR

FOR

**3D-CARDIAC TISSUE ENGINEERING
FOR THE CELL THERAPY OF HEART FAILURE**

1803072_v1

3D-CARDIAC TISSUE ENGINEERING FOR THE CELL THERAPY OF HEART FAILURE

Background of the Invention

The invention is generally in the field of tissue engineering and in particular relates to methods and compositions for repair of heart tissue by implantation of stem cell.

New steps in regenerative medicine are showing the first advances in the application of stem cells for tissue regeneration. Up to now, cardiac tissue engineering utilizes cells seeded into polymeric scaffolds to try to reproduce the myocardial structure and properties. However, among other problems, neovascularization is still a limiting factor while using conventional tissue scaffolds. Heart failure caused by myocardial infarction may be successfully treated in human beings by cell therapy using a multidisciplinary approach combining expertise in stem cells biology, tissue engineering as well as non-invasive cardiac imaging.

Over the past few years, research on animal and human stem cells (either embryonic, fetal or adult stem cells) has experienced tremendous advances which are almost daily loudly revealed to the public on the front-page of newspapers. The reason for such an enthusiasm over stem cells is that they could be used to cure patients suffering from spontaneous or injuries-related diseases that are due to particular types of cells functioning incorrectly, such as cardiomyopathy, diabetes mellitus, osteoporosis, cancers, Parkinson's disease, spinal cord injuries or genetic abnormalities. This new concept of "regenerative medicine" by stem cells therapies is unprecedented since it involves the regeneration of normal cells, tissues and organs which could allow treating patients.

Embryonic stem cells derived from the embryo at the blastocyst stage are defined as pluripotent since they have the tremendous ability to self-renew and also to differentiate into a variety of cells of all 3 germ layers¹. Adult stem cells present in some organs of the adult body also have some regenerative capacities (i.e. satellite cells and bone marrow cells). However their potential to

transdifferentiate to phenotypes different from those to which they are pre-committed seems so far more restricted ^{2,3}. For this reason, they are defined as multipotent. On the other hand, these cells would allow autologous cell transplantation avoiding problems of rejection and immunosuppressive drugs.

- 5 Therefore, research on both type of stem cells is complementary and needs to be pursued in parallel.

Heart failure is the number one cause of death in industrialized countries. Myocardial infarction typically results in fibrotic scar formation and permanently impaired cardiac function because, after a massive cell loss due to ischemia, the myocardial tissue lacks intrinsic regenerative capability. Thus, efforts to regenerate functional myocardial tissue are being firstly pursued through cell grafting. The principal feasibility of cardiac cell implantation in the heart has been achieved nearly 10 years ago ⁴⁻⁶. Thereafter, several groups have enlarged our knowledge about the fate of implanted cells of various origin (embryonic, fetal or adult) in the myocardium of healthy and diseased heart (reviewed in ⁷. Most studies support the notion that cell engraftment in models of myocardial infarction can improve contractile function ⁸. There are presently several ongoing clinical studies in humans using adult stem cells (skeletal myoblasts, bone marrow stem cells) to investigate the safety and feasibility of such a cardiac cell therapy ⁹. However, there is still no convincing demonstration for a transdifferentiation to the cardiac phenotype of such adult stem cells. So far, first clinical results are still controversial and demonstrated the need to better understand the stem cell biology.

Cardiac tissue engineering includes the fields of material sciences and cell biology. It has emerged as an alternative promising approach to replace or support an infarcted cardiac tissue and thus may hold a great potential to treat and save the lives of patients with heart diseases. Tissue engineering involves the construction of tissue equivalents from donor cells seeded within 3D biomaterials, then culturing and implanting the cell-seeded scaffolds to induce and direct the growth of new, healthy tissue. Tissue-engineering technologies

have therefore the potential to revolutionize soft-tissue reconstruction by creating biologically based tissue replacements.

After myocardial infarction, the lost cardiomyocytes due to a lack of vascularization are replaced by a scar formed by fibrotic tissue. The surviving cardiac cells undergo neurohormonal-induced hypertrophy as a compensatory mechanism in order to maintain a demanded cardiac output. The heart wall becomes thinner and the ventricle dilates, leading to an end-stage congestive heart failure. Therefore the possibility to repopulate these infarcted areas would be essential for the restoration of a functional contracting myocardium.

Repopulation of these tissues by the application of extracellular matrix-based gels engineered with stem cells is the goal. The plasticity of the stem cells and the presence of appropriate cytokines and growth factors will enable to guide the differentiation of the stem cells into functional cardiomyocytes. Furthermore, the addition of other growth factors will enable us to provide the region with an enhanced vascularization, necessary for the viability of the patch and the integration into the myocardium.

Cardiac tissue engineering methods typically utilize cells seeded into or onto polymeric scaffolds¹⁰⁻¹². Reproducing the special organizational, mechanical, and elastic properties of native myocardium represents a significant challenge from the perspective of tissue engineering scaffolds. Ideally, these constructs display properties of native myocardium such as coherent contractions, low diastolic tension, and syncytial propagation of action potentials. To be applicable for surgical repair of diseased myocardium engineered tissue constructs should have the propensity to integrate and remain contractile *in vivo*. In order to better meet the mechanical demands of force-generating contractile tissue, biodegradable materials such as hydrogels may serve as more appropriate scaffolds for transplantation of organized cardiac tissue constructs to the heart for myocardial repair.

Recent attempts to engineer soft tissue include the use of scaffolds manufactured from natural polymers, such as collagen,¹³ gelatin, alginate¹⁹ hyaluronic acid²⁰, and chitosan²¹ gels or synthetic, biodegradable polymers^{22,23}.

So far, various methods to produce 3D-cardiac tissue constructs have been proposed ¹³⁻¹⁸, but the reconstruction of a functional heart tissue remains to be achieved. In particular, problems with vascularization still limit the use of conventional tissue scaffolds in the replacement of large-size tissue defects.

5 Clearly, cardiac tissue engineering for replacement therapy has an emerging technology still in its early days due to the complexity of the heart tissue. Its true value remains to be thoroughly evaluated.

It is therefore an object of the present invention to create 3D-engineering gels allowing angiogenic and cardiac differentiation of trapped stem cells for the therapy of heart diseases.

10

Summary of the Invention

Cardiac patches have been developed using extracellular-based gels containing stem cells positioned on a heart surface as a cell therapy to treat heart failure and renewal of infarcted tissue. The incorporation of bioactive and biodegradable materials locally releasing appropriate growth factors and cytokines into the material in which stem cells are seeded support and improve the differentiation of embryonic stem cells (ESC) into viable cardiomyocytes and allow endothelial progenitor cells (EPCs) to build a vascular bed.

15

Detailed Description of the Invention

20 A. Gel-Based Matrices and Biomaterials

Bioactive materials are materials which incorporate growth factors or cytokines and are able to release them either at a controlled ratio or directly on cell demand. Extracellular matrix (ECM) components like fibrin or collagen, or synthetic polymers mimicking the ECM, like the polyethylenglycol-modified polymers, can be used as vehicles for cell transplantation. These materials offer the cells an environment providing adhesion natural sites, eventually growth factors and cleavage sites enabling the cells to substitute the material while proliferating and migrating.

25

Native ECMs components such as fibrinogen from human plasma are particularly useful since it can be cleaved by thrombin into its fibrin subunits. After cleavage a self-assembly step occurs in which the fibrinogen monomer

30

come together and form a non-covalently cross-linked gel via proteolytic exposure of binding sites. The covalent crosslinking of the chains is achieved via factor XIIIa, which is a transglutaminase. Through factor XIIIa it was shown that other proteins like fibronectin or collagen can be bound ²⁴⁻²⁶.

- 5 By protein-engineering it is possible to produce growth factors and cytokines, which has an alpha2-plasmin inhibitor sequence in their N-terminus. Gels containing such "architectures, can trap growth factors and cytokines, which can be subsequently cleaved on cell demand ^{27,28}. Therefore, the degradation ratio of the gel as well as the release of growth factors will be cell proliferation
10 dependent.

B. Cells for cardiac repair

- Cardiomyocytes are the main cellular component but non-muscle cells (such as endothelial cells, fibroblasts, smooth muscle cells and leukocytes) play an important role in cardiac development and function ²⁹⁻³¹. The exact
15 contribution of each single cell type to tissue-formation has not been deeply analyzed yet, but the data strongly suggest that formation of a true cardiac tissue-like 3D construct requires the presence of cardiac myocytes and non-myocytes in physiological mix.

1) Cardiomyocytes derived from ESC

Embryonic stem cells (ESC) are pluripotent cells derived from the inner cell mass of the blastocyst. Therefore they have the ability to differentiate into many kind of cell lineage, a capacity that becomes progressively restricted with development. Unlimited differentiation capacity and indefinite propagation represent the strongest advantages of ESC.

Pluripotent ESC are able to differentiate *in vitro* into structures called embryoid bodies (EBs). During this differentiation process, ESCs develop into a variety of committed cell lineages originating from mesoderm, ectoderm and endoderm. Therefore, the possibility to isolate, from differentiating, embryonic cardiomyocytes that are still in a proliferative phase³² offers a tremendous advantage. Several studies have demonstrated the possibility to engraft such cells into animal models of heart failure^{4,7} with encouraging results. Since the derivation in 1998 of human ESCs lines from pre-implantation embryos³³, considerable research is centered on their biology, in particular on how to encourage a specific cell differentiation^{34,35} and also on means to enrich and purify derivative cell types such as cardiomyocytes³⁶. Autograft cells are preferred, but allograft cells can be utilized, with appropriate selection and utilization of immunosuppressants, such as those currently in use following tissue or organ transplantation.

2) EPCs-dependent vascularization

Endothelial progenitor cells (EPCs) isolated from bone marrow³⁷, peripheral³⁸ or cord blood³⁹ were shown to play a crucial role in many physiological and pathological situations. These cells participate to complex processes like angiogenesis and arteriogenesis⁴⁰, which are important steps in vascular repair. The involvement of these cells in the neovascularization of tissues was observed in animal models during tumor development⁴¹ as well as during therapeutic angiogenic assays⁴². These cells have shown promising results when transplanted in ischemic limb⁴³ and into the heart⁴⁴.

EPCs are known for their high proliferation rate and capability to support angiogenesis and revascularization in ischemic tissues^{37,43} and differentiate into

the terminal phenotype of endothelial cells (ECs). Their proliferative potential, when compared to the one of endothelial cells, as well as their differentiation pathways into endothelial cells, smooth muscle cells and cardiomyocytes, makes them suitable candidates for the implantation in infarcted hearts. However, to
5 completely restore cardiac function in infarcted areas EPCs seems not to be sufficient, because it was shown that only in presence of cardiomyocytes, this transdifferentiation is possible.

Although many publications in the field of therapeutic angiogenesis appeared during the last years, few were dedicated to the study of the interaction
10 of EPCs, the extracellular matrix (ECM) and the growth factors. The assessment of stem cell therapy requires serial measurements of myocardial function, perfusion, viability and cell tracking.

C. Method of Implanting and Assessing Function

Echocardiography is well established to measure myocardial function.
15 Single photon emission computed tomography (SPECT) and positron emission tomography (PET) can also determine myocardial perfusion and metabolism. However, they are not able to resolve transmural analysis of the myocardium wall. In addition, dedicated set-up is needed for small animal imagings that are not widely available.

20 Recently, magnetic resonance imaging (MRI) has emerged as a promising and recognized tool for cardiac imaging as it will be further developed. MRI is now accepted as a gold standard for the assessment of the cardiac anatomy and volumes including the ejection fraction (EF) and cardiac output. Cine MRI provides a highly reproducible protocol to assess the
25 myocardial contraction. Using special saturation pulses, the myocardium can be tagged for quantitative measurement of regional strains ⁴⁶. MRI is also very sensitive to myocardial perfusion when first-pass contrast media study are performed ⁴⁷. Finally, new MRI myocardial viability methods have been validated using contrast media as gadolinium chelates induce a
30 hyperenhancement of infarct myocardium ⁴⁸. MRI assessment of viability

correlates with PET for transmural infarct but appears to detect subendocardial infarction missed by PET ⁴⁹.

As the MRI contrast and resolution between types of cells is limited, a new strategy has been developed to monitor *in vivo* specific groups of cells.

5 Since the *in vivo* uptake of MRI contrast media can not be tailored to any types of cells, *ex-vivo* cells are typically labeled using paramagnetic or superparamagnetic iron oxide (SPIO) contrast media. After implantation, the labeled cells locally destroy the magnetic field homogeneity. This results on dark spots that can be detected using dedicated MRI sequences ⁵⁰. However, the
10 assessment is largely qualitative based on the presence or absence of the dark spots. A quantitative assessment of the contrast media and cells distribution in the tissue remains a significant and largely unresolved challenge.

***In vitro* cell labeling**

Presently, two types of MR contrast agents are used clinically:
15 gadolinium-analogues and iron oxide nanoparticles. These agents are particularly designed as blood-pool contrast agents which are impermeable to cells. Recently, superparamagnetic nanoparticles of anionic $\gamma\text{-Fe}_2\text{O}_3$ (iron oxide) have been shown to label efficiently different types of cells due to the negative surfaces charges. These particles are thus particularly suited for cellular
20 imaging *in vivo*, due to a near-cellular (i.e. 20-50 microns) resolution, long half-life and low local or systemic toxicity. However their uptake by cells still needs to be improved, for example using lipofection agents ^{51,52}. A preferred magnetic labeling approach is based on the use of the FDA-approved SPIO formulation Ferridex, mixed with a transfection agent ⁵¹. A recent work by Hoehn *et al* used
25 such a labeling to track GFP-expressing ESC (green fluorescent protein), by MRI upon implantation into an ischemic rat brain ⁵².

***In vivo* cell tracing in the heart**

So far, two studies have already demonstrated the feasibility for the *in vivo* detection of labeled stem cells in the heart ⁵³. Both studies used a swine
30 model of myocardial infarction on a limited number of animals. Injection of 10^6 labeled stem cells generated detectable signal void using clinical 1.5T MRI

scanner that was no longer visible at 3 weeks⁵³. The effect of the stem cells on the myocardial infarct was not assessed in these preliminary studies.

The present invention will be further understood with reference to the following studies.

5 **Example 1: Preparation of Cardiac Patches**

Methods and preliminary results

Experiments were performed which establish the feasibility of growing mouse ESC, as well as differentiating ESC within embryoid bodies and neonatal cardiomyocytes into 3D-fibrin gels. Ongoing studies on the differentiation of
10 EPC show that the presence of vascular endothelial growth factor (VEGF) is preferred for their differentiation into mature endothelial cells. Indeed, EPC have the capability to create tube-like constructs in fibrin gels in presence of the epidermal growth factor (EGF).

In vivo properties of the 3D cardiac patches were studied. One
15 fundamental question is to investigate the fate of stem cells after implantation to (i) map the spatial distribution, (ii) measure the rate of migration *in situ*, and (iii) monitor the survival of the grafted cardiac patches. To this end, protocols are drawn up for the labeling of cells with nanoparticles of iron oxide in order to study their biology *in vitro* and to trace them after implantation *in vivo*.

20 1) Set-up of *in vitro* cells labeling protocols using MRI contrast media. First, commercially available contrast media will be used for toxicity and adverse effects on cellular function studies. In a second step, new engineered contrast media are investigated to improve the specificity of the cells labeling.

25 2) Development of a quantitative MRI protocol to measure the amount of contrast media inside the cells.

 3) Assessment of the *in vivo* spatial and temporal distribution of the labeled cells.

 These new contrast media derived from iron nanoparticles are coated with specific antibodies or peptides. The engineered surface of the contrast
30 media are thus modified to improve the internalization of the product. Enhanced efficiency as well as increased specificity of the internalization is expected. In

addition, fluorescein probe are also added to obtain a dual contrast agent that enables the live cell monitoring and ease the correlation between histopathological examination and MRI.

Methods and preliminary results:

5 Prussian blue staining, electron microscopy and spectrophotometry to evaluate the nanoparticles inside the cells and determine the tolerance of the ES cells to the paramagnetic label are used.

10 The feasibility of rat heart imaging by MRI at 1.5 T are illustrated by the performance of serial *in vitro* MR imaging of labeled cells suspended in fibrin gels within a spectrophotometric cuvette to develop a quantitative protocol to measure the iron content inside the cells. This MR protocol is applied to measure the time evolution of the iron concentration *in vivo* after the cardiac patches engraftment.

15 The applicability of cell containing-3D fibrin gels into infarcted areas of a rat model of myocardial infarction in order to replace nonfunctional diseased cardiac tissue are evaluated, in particular by performing *in vivo* MRI monitoring of the 3D-labeled cardiac patches after heart implantation to define the bio-distribution of the stem cells in correlation to the cardiac function and infarct evolution.

20 Examining *ex-vivo* the transplanted heart by immunohistochemical techniques to evaluate cell fate and biodistribution.

Methods and preliminary results:

25 In preliminary tests the feasibility of fixing empty fibrin gels on the left ventricle of normal hearts was examined. Furthermore, in a first attempt to engraft a gel containing undifferentiated ESC, cell survival and proliferation were observed for up to 2 weeks.

Materials and Methods

30 The 3-D gel systems used for manufacture of the cardiac patches are based on extracellular matrix proteins, the gel systems have the following properties;

E-Modulus (elastic characteristics): 30-80kPa

Type of material: gel-like material with high water content, typically of 90 to 95%.

The 3D gel systems are designed so that different types of cells can be employed and combined within the gels: (i) embryonic stem cells committed to a cardiac phenotype, and (ii) adult stem cells (such as endothelial progenitors cells), able to improve the neovascularization of the damaged tissue and/or to transdifferentiate to the cardiac phenotype.

Example of adult stem cells: isolation of MNCs and CD34+ cells from human umbilical cord blood (UCB)

UCB cell collection was approved by the ethical committee of the University Hospital Zurich. Typically, 50 mL of UCB could be collected from fresh placentas with umbilical cord into Vacutainer tubes containing citrate as anticoagulant. The UCB was diluted with two volumes of Ca^{2+} - and Mg^{2+} -free Dulbecco PBS (D-PBS). Mononuclear cells (MNCs) were isolated by density gradient centrifugation with Biocoll (Oxid AG, Basel, Switzerland), then washed 3 x in D-PBS. Positive selection of CD34+ was performed by a magnetic bead separation method (MACS; Miltenyi Biotec, Gladbach, Germany), using the manufacturer's protocol.

Culture of Endothelial Progenitor Cells (EPCs)

2×10^4 MACS-selected CD133+ cells were plated on 8-well glass culture dishes (Nunc Lab-TekTMII Chamber slide system; VWR International AG, Dietikon, Switzerland) coated with 10 ng/mL human fibronectin (Bioreba, Basel, Switzerland) and 1% gelatin, or fibrin gel substrates. Cells were seeded in endothelial cell growth medium (EC) (C-22010; Clontech, Palo Alto, CA; this medium initially contains 2% FBS and the additive C-39215) supplemented to 20% fetal calf serum (FCS). Cultures were grown at 37°C, 5% CO_2 , in a humidified atmosphere. After 24 hr, the non-adherent cells were removed from adherent cells via careful replacement of medium with fresh EC medium.

Growth of EPCs on two-dimensional fibrin gel for cardiac implants

100 μL fibrin gel substrates were formed at the bottom glass of tissue culture chambers (Nunc Lab-TekTMII Chamber slide system). Epidermal growth

factor (EGF), or VEGF₁₆₅ were admixed to fibrin gel substrate at 150 ng/mL gel. Control fibrin substrates were prepared with neither growth factor. 2×10^4 MACS-selected CD133+ cells were seeded in 400 μ L Clontech EC medium atop the fibrin gel substrates formulated with growth factors. Assuming an even
5 distribution of freely diffusing EGF or VEGF₁₆₅ between fibrin gel substrate and overlaying culture medium, this resulted in an initial concentration of 50 ng/mL EGF or VEGF₁₆₅ in the culture system. The culture medium was changed after 24 hr. A second change of medium after another 48 hr was found critical for cell survival. Subsequent changes of EC culture medium were performed after 48 hr
10 or 72 hr. In each change, 350 μ L culture supernatant were removed and replaced with an equal volume of fresh EC medium. These changes of medium resulted in removal of EGF and VEGF and the concomitant decrease of EGF or VEGF₁₆₅ concentrations in the culture system. The concentrations of growth factors were calculated to be 21 ng/mL after the first change of medium, and 8.8 ng/mL, 3.7
15 ng/mL and 1.5 ng/mL after the second, third, and fourth change, respectively. After 14 days of cultivation a substantial part of the gel was proteolized, therefore, in order to implant the gels on the top of the infracted area a 1% fibrin gel was added on top of the cells. After extraction of the gel from the well, these were implanted in the infracted area and fixed with two sutures on the
20 myocardium.

An analogous procedure was applied for embryonic stem cells and other adult stem/progenitor cells used. ESC stable clones containing the CD63-GFP marker gene were used to isolate green ESC-derived cardiomyocytes upon differentiation within embryoid bodies. 3D-fibrin gels containing
25 undifferentiated CD63-GFP ESC were monitored at day 0 and 4 days later. This allowed researchers to follow their fate *in vitro* within the gels (either alone or in combination with EPCs), as well as to identify them *in situ* after their engraftment. Gels containing embryoid bodies (EBs) formed by mouse ESC were preincubated for 6 days to allow cardiac differentiation. With time (up to 6
30 days) the EBs within the gels spread and cells migrated. Similarly, freshly dissociated and purified neonatal rat cardiomyocytes redifferentiate over time

(up to 14 days) in the 3D gels and remain viable for weeks in culture, forming a network of spontaneously beating cells.

Example 2: Implantation in a Rat model of myocardial infarction

Male Sprague-Dawley rats weighing 300-350 grams were initially
5 anesthetized with 4-5% isoflurane in an induction chamber. Following the
shaving and weighting, the rat was intubated with a 14-gauge catheter, tracheal
ventilation was performed at 70 cycles/min with 2.5-3.0mL tidal volume, room
air supplemented with oxygen (Harvard Rodent Ventilator, Model 683, Harvard
Apparatus Co, Inc). 1.5-2% isoflurane was maintained for continuous
10 anesthesia.

Three electrodes were positioned to record the electrocardiographic
tracing (ECG) monitor. The respiration curve was also recorded during all
procedure.

A left intercostal thoracotomy was performed under aseptic technique.
15 The fourth intercostal space was opened carefully to avoid accidentally cutting
any vessels including the internal mammary artery. The fourth and fifth ribs
were separated with a small retractor (Harvard Apparatus, France) to explore the
heart. The pericardium was removed, the left anterior descending artery and its
branch was observed under surgical microscope. A 6-0 polypropylene snare was
20 made passing through the epicardium layer around the origin of the artery
between the left atrium and the right pulmonary outflow tract, tying the ligature
permanently occluded the artery. After LAD ligature, the left ventricular anterior
free wall becomes hypokinetic and clearer due to the cyanosis.

The muscle layer and skin were closed with 3-0 suture afterwards.
25 Before the rat woke up completely, extubation was performed and the rat was
placed in a recovery cage with a supply of oxygen for 30 to 60 minutes.

Transplantation Procedure

3D cardiac patches implantation was performed into two different
conditions of the rats: with or without myocardial infarction. Echo study was
30 performed for left ventricular function evaluation in MI rats. 1 week, 4 or 8
weeks after implantation, the rats were sacrificed and the histologic and

pathologic studies were performed. To evaluate the transformation of left ventricular function, the echocardiograph study was performed to the rats with infarction the day before cells grafting and the day before sacrificing respectively.

5 Engraftments were performed on the normal hearts, immediately after coronary ligation, 1-week or 4 weeks after myocardial infarction. After 2 weeks, the immunohistochemistry staining revealed a gel full of proliferating ESC, positive for the proliferating cell nuclear antigen (PCNA) and the GFP marker.

10 Rats were anesthetized, and under sterile technique, the chest was re-opened. The infarcted area was identified visually on the basis of surface scar and wall motion abnormality. 3D patches are applied and fixed onto the of the left ventricular anterior free wall. Control animals received empty 3D patches.

Immunosuppression treatment

15 To prevent rejection and assess the effect of an immunosuppression treatment on stem cell fate, groups of rats received immunosuppression agent cyclosporin A delivered continuously via an osmotic minipump (ALZA Corporation). Alzet mini-osmotic pumps were filled with cyclosporin A (CsA) (Sandimmune, Novartis 50mg/1ml), and was kept overnight at 37°C in PBS
20 before implantation. The CsA release was adjusted at 2.5µl/hour or 10µl/hour and pump were designed for a 7- or 28-days release. The administrated dosage of CsA was calculated as 6-9 mg/Kg/day. After hair shaving and skin cleaning at the site for incision, a hemostat was inserted into the incision to spread the subcutaneous tissue and create a prompt pocket for the pump. The filled pump
25 was implanted subcutaneously and the wound closed with suture. All procedure was performed under sterile circumstances.

Evaluation of the left ventricular function by echocardiography

 For the evaluation of left ventricular function, transthoracic echocardiogram was performed on the rats after myocardial infarction 1 week or
30 4 weeks right before implantation (baseline echocardiogram), and 1 week or 4 weeks after implantation, before the sacrifice of the animals. Rats were

anesthetized with 4-5% isofluorane in an induction chamber. The chest was shaved, the rats were placed in dorsal decubitus position and intubated for continuous ventilation. 1-2% isofluorane was continuously supplied via a mask. 3 electrodes were adhered to their paws to record the electrocardiographic tracing simultaneously with the cardiac image identifying the phase of a cardiac cycle.

Echocardiograms were performed with a commercially available echocardiography system equipped with 7.5 MHz phased-array transducer (Philips-Hewlett-Packard). The transducer was positioned on the left anterior side of the chest. At first, longitudinal images of the heart were obtained, including the left ventricle, atrium, the mitral valve and the aorta, followed by the cross-sectional images from the plane of the base to the left ventricular apical region. M-mode tracings were obtained at the level below the tip of the mitral valve leaflets at the level of the papillary muscles. All of two-dimensional images, M-mode tracings and Doppler curves were recorded on videotape for later analysis. We calculated the fractional shorting (FS) as a measure of systolic function, according to the M-mode tracing from the cross-sectional view: maximal LV end-diastolic diameter (at the time of maximal cavity dimension), minimal LV end-systolic diameter (at the time of maximum anterior motion of the posterior wall), $FS (\%) = \{(LVEDD - LVESD) / LVEDD\} \times 100$. All measurements were averaged for 3 consecutive cardiac cycles.

Preliminary results

Experiments established the feasibility of growing mouse ESC, as well differentiating ESC within embryoid bodies and neonatal cardiomyocytes into 3D-fibrin gel systems. Figure 1 shows a pictorial representation of the different multi-well (Fig. 1a) systems used to produce the 3D-fibrin gels. Furthermore, the ongoing studies on the differentiation of EPC show the importance of the presence of vascular endothelial growth factor (VEGF) in the differentiation of the stem cells into mature endothelial cells. Indeed, EPC have the capability to create tube-like constructs in fibrin gels in presence of the epidermal growth factor (EGF).

The feasibility of fixing empty 3D fibrin gel systems on the left ventricle of normal hearts. Furthermore, in an attempt to engraft a 3D fibrin gel system containing undifferentiated ESC, cell survival and proliferation for up to 2 weeks were observed.

- 5 Cell therapy of heart failure is presently performed with adult stem cells (form bone marrow or skeletal muscle compartment) has entered recently clinical phase 1 trials. However, cell injection via a syringe is highly ineffective and results in the loss of more than 95% of the cells. The cardiac patches allow a better survival and the correct insertion of the appropriate cells where the
- 10 tissue need to be regenerated. Furthermore, the vascularization of these tissues is of main importance for the repopulation of the damaged heart and thus the patient survival. Another crucial advantage is the fact that the gels are formed by extracellular matrix proteins present in normal tissues and biodegradable by endogenous and cell-released proteases.

F. References

1. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. *Cell*. 2000;100:157-68.
- 5 2. Anderson DJ, Gage FH, Weissman IL. Can stem cells cross lineage boundaries? *Nat Med*. 2001;7:393-5.
3. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. *Science*. 2002;297:2256-9.
- 10 4. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. *J Clin Invest*. 1996;98:216-24.
5. Koh GY, Soonpaa MH, Klug MG, Pride HP, Cooper BJ, Zipes DP, Field LJ. Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. 15 *J Clin Invest*. 1995;96:2034-42.
6. Koh GY, Soonpaa MH, Klug MG, Field LJ. Strategies for myocardial repair. *J Interv Cardiol*. 1995;8:387-93.
7. Dowell JD, Rubart M, Pasumarthi KB, Soonpaa MH, Field LJ. Myocyte and myogenic stem cell transplantation in the heart. *Cardiovasc Res*. 20 2003;58:336-50.
8. Passier R, Mummery C. Origin and use of embryonic and adult stem cells in differentiation and tissue repair. *Cardiovasc Res*. 2003;58:324-35.
9. Menasche P. Myoblast-based cell transplantation. *Heart Fail Rev*. 2003;8:221-7.
- 25 10. Nugent HM, Edelman ER. Tissue engineering therapy for cardiovascular disease. *Circ Res*. 2003;92:1068-78.
11. Eschenhagen T, Didie M, Heubach J, Ravens U, Zimmermann WH. Cardiac tissue engineering. *Transpl Immunol*. 2002;9:315-21.
12. Zimmermann WH, Eschenhagen T. Cardiac tissue engineering for 30 replacement therapy. *Heart Fail Rev*. 2003;8:259-69.

13. Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J, Eschenhagen T. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. *Biotechnol Bioeng.* 2000;68:106-14.
14. Leor J, Aboulafia-Etzion S, Dar A, Shapiro L, Barbash IM, Battler A, Granot Y, Cohen S. Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium? *Circulation.* 2000;102:III56-61.
15. Dar A, Shachar M, Leor J, Cohen S. Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffolds. *Biotechnol Bioeng.* 2002;80:305-12.
- 10 16. Shimizu T, Yamato M, Kikuchi A, Okano T. Cell sheet engineering for myocardial tissue reconstruction. *Biomaterials.* 2003;24:2309-16.
17. Shimizu T, Yamato M, Isoi Y, Akutsu T, Setomaru T, Abe K, Kikuchi A, Umezumi M, Okano T. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. *Circ Res.* 2002;90:e40.
- 15 18. Zimmermann WH, Didie M, Wasmeier GH, Nixdorff U, Hess A, Melnychenko I, Boy O, Neuhuber WL, Weyand M, Eschenhagen T. Cardiac grafting of engineered heart tissue in syngenic rats. *Circulation.* 2002;106:II51-7.
- 20 19. Burg KJ, Holder WD, Jr., Culbertson CR, Beiler RJ, Greene KG, Loebbeck AB, Roland WD, Eiselt P, Mooney DJ, Halberstadt CR. Comparative study of seeding methods for three-dimensional polymeric scaffolds. *J Biomed Mater Res.* 2000;52:576.
- 25 20. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. *Dermatol Surg.* 1998;24:1317-25.
21. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux JC, Atkinson BL, Binette F, Selmani A. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. *Biomaterials.* 2000;21:2155-61.
- 30

22. Holder WD, Jr., Gruber HE, Moore AL, Culberson CR, Anderson W, Burg KJ, Mooney DJ. Cellular ingrowth and thickness changes in poly-L-lactide and polyglycolide matrices implanted subcutaneously in the rat. *J Biomed Mater Res.* 1998;41:412-21.
- 5 23. Brown AN, Kim BS, Alsberg E, Mooney DJ. Combining chondrocytes and smooth muscle cells to engineer hybrid soft tissue constructs. *Tissue Eng.* 2000;6:297-305.
24. Schense JC, Hubbell JA. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. *Bioconjug Chem.* 1999;10:75-81.
- 10 25. Ye Q, Zund G, Benedikt P, Jockenhoevel S, Hoerstrup SP, Sakyama S, Hubbell JA, Turina M. Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. *Eur J Cardiothorac Surg.* 2000;17:587-91.
26. Hall H, Baechi T, Hubbell JA. Molecular properties of fibrin-based matrices for promotion of angiogenesis *in vitro*. *Microvasc Res.* 2001;62:315-15 26.
27. Schense JC, Bloch J, Aebischer P, Hubbell JA. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. *Nat Biotechnol.* 2000;18:415-9.
28. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA. 20 Covalently conjugated VEGF--fibrin matrices for endothelialization. *J Control Release.* 2001;72:101-13.
29. Long CS, Henrich CJ, Simpson PC. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. *Cell Regul.* 1991;2:1081-95.
30. Shah AM, Grocott-Mason RM, Pepper CB, Mebazaa A, Henderson AH, 25 Lewis MJ, Paulus WJ. The cardiac endothelium: cardioactive mediators. *Prog Cardiovasc Dis.* 1996;39:263-84.
31. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. *Cardiovasc Res.* 1998;40:352-63.

32. Meyer N, Jaconi M, Landopoulou A, Fort P, Puceat M. A fluorescent reporter gene as a marker for ventricular specification in ES-derived cardiac cells. *FEBS Lett.* 2000;478:151-8.
33. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ,
5 Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science.* 1998;282:1145-7.
34. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. *Stem Cells.* 2001;19:193-204.
35. Jones JM, Thomson JA. Human embryonic stem cell technology. *Semin*
10 *Reprod Med.* 2000;18:219-23.
36. Pasumarthi KB, Field LJ. Cardiomyocyte enrichment in differentiating ES cell cultures: strategies and applications. *Methods Mol Biol.* 2002;185:157-68.
37. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M,
15 Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med.* 1999;5:434-8.
38. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzendichler B, Schatteman G, Isner JM. Isolation of putative progenitor
20 endothelial cells for angiogenesis. *Science.* 1997;275:964-7.
39. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J Clin Invest.* 2000;105:1527-36.
40. Schmeisser A, Strasser RH. Phenotypic overlap between hematopoietic
25 cells with suggested angioblastic potential and vascular endothelial cells. *J Hematother Stem Cell Res.* 2002;11:69-79.
41. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A.*
30 2000;97:3422-7.

42. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. *J Clin Invest.* 1994;93:662-70.
- 5 43. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet.* 2002;360:427-35.
- 10 44. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. *Circ Res.* 2002;90:E89-93.
45. Hoffmann R, Lethen H, Marwick T, Arnesen M, Fioretti P, Pingitore A, Picano E, Buck T, Erbel R, Flachskampf FA, Hanrath P. Analysis of
15 interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. *J Am Coll Cardiol.* 1996;27:330-336.
46. Croisille P, Moore CC, Judd RM, Lima JA, Arai M, McVeigh ER, Becker LC, Zerhouni EA. Differentiation of viable and nonviable myocardium by the use of three- dimensional tagged MRI in 2-day-Old reperfused canine
20 infarcts. *Circulation.* 1999;99:284-291.
47. Al-Saadi N, Nagel E, Gross M, Bornstedt A, Schnackenburg B, Klein C, Klimek W, Oswald H, Fleck E. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. *Circulation.* 2000;101:1379-83.
- 25 48. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med.* 2000;343:1445-53.
49. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F,
30 Schnackenburg B, Delius W, Mudra H, Wolfram D, Schwaiger M. Assessment

of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. *Circulation*. 2002;105:162-7.

50. Pautler RG, Fraser SE. The year(s) of the contrast agent - micro-MRI in the new millennium. *Curr Opin Immunol*. 2003;15:385-92.

5 51. Frank JA, Zywicke H, Jordan EK, Mitchell J, Lewis BK, Miller B, Bryant LH, Jr., Bulte JW. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. *Acad Radiol*. 2002;9:S484-7.

52. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S,
10 Focking M, Arnold H, Hescheler J, Fleischmann BK, Schwindt W, Buhrle C. Monitoring of implanted stem cell migration *in vivo*: a highly resolved *in vivo* magnetic resonance imaging investigation of experimental stroke in rat. *Proc Natl Acad Sci U S A*. 2002;99:16267-72.

53. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ,
15 Pittenger MF, Hare JM, Bulte JW. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. *Circulation*. 2003;107:2290-3.